CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 116 enrolled
Drug / intervention
HTX-011 +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03974932
NCT03974932Phase 3Completed

A Phase 3b, Open-Label Study of HTX-011 as Part of a Scheduled Non-Opioid Multimodal Analgesic Regimen in Subjects Undergoing Total Knee Arthroplasty

Heron Therapeutics·interventional·Posted Jun 5, 2019·Updated Mar 2, 2026

In Brief

A Phase 3 clinical trial evaluating HTX-011, Ibuprofen, and 4 other interventions for Analgesia. Completed, enrolled 116 participants across 6 sites.

Detailed Summary

Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnalgesia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJun 5, 2019
Enrollment StartJun 5, 2019
Primary CompletionDec 7, 2020
Study CompletionJan 7, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.1 years ago

Interventions

HTX-011drug

Dual-acting local anesthetic. Dose 1.

Ibuprofendrug

NSAID.

Acetaminophendrug

Analgesic.

Celecoxibdrug

NSAID.

+/- Bupivacaine HCldrug

Local anesthetic.

Luer Lock Applicatordevice

Applicator for instillation.

HTX-011drug

Dual-acting local anesthetic. Dose 2.